Tags : Access

Biosimilars

Alvotech and Cipla Collaborate to Ensure Access to Biosimilars in

Shots: Alvotech and Cipla entered an exclusive partnership to provide patients with better access to high quality and cost-effective biosimilar medicines in South Africa Alvotech will be responsible for the development and supply of the products and Cipla will be responsible for the registration and commercialization The biosimilar portfolio will include five biosimilars- two for […]Read More

Biotech

Roche and Cipla Expand Their 2018 Agreement to Improve Access

Shots: Cipla expands partnership with Roche to improve access to key oncology medicines which include Herclon (trastuzumab), Avastin (bevacizumab) and Ristova (rituximab) in India. Cipla will be responsible for the marketing and distribution of Roche’s key products In Feb’2018, the two companies collaborated for the promotion and distribution of Actemra (tocilizumab) and other products  The […]Read More

Biotech

MSD Signs a Multiyear Agreement with Just – Evotec Biologics

Shots: Just-Evotec to receive $15M up front, milestones on completion of the construction of the J.POD facility (facility of the future) as well as a broad collaboration around reserved capacities Just – Evotec Biologics granted MSD access to manufacturing capacity in the J.POD facility in Redmond, Washington, which was co-developed by MSD and Just Biotherapeutics […]Read More

Pharma

Pfizer Collaborates with Centogene to Access its Rare Disease Data

Shots: Centogene to receive up front and will be eligible for additional research payments for any future collaboration. Pfizer to get access to CENTOGENE’s data repository, which may be used to discover and validate new therapies targeting rare diseases The companies will work together in mining the data repository and jointly agree for any research […]Read More

Pharma

LEO Pharma Signs an Option Agreement with Ubiquigent to Access

Shots: Ubiquigent to receive up front, option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to […]Read More

Pharma

NHS England Signs an Agreement with Vertex to Access All

Shots: The agreement allows CF patients aged ≥2yrs.with two copies of F508del mutation in CFTR gene to access Orkambi (lumacaftor/ivacaftor) and CF patients aged ≥12yrs. with either two or one copy of F508del mutation and copy of one of the other 14 licensed mutations to access Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in England The […]Read More

Biosimilars

WHO Signs MoU with IGBA for Promoting the Access to

Shots: The memorandum of understanding signed between WHO and International Generic and Biosimilar Medicines Association to facilitates the approval of generics and biosimilars thus reduces the burden of clinical trials for biosimilars and increases the access to drugs The WHO’s efforts to increase the access to Biosimilar includes List of International Comparators, providing information on […]Read More

Biotech

IBRI Signs a License Agreement with Eli Lilly to Access

Shots: The Indiana Biosciences Research Institute collaborates with Lilly to identify new Ab & to validate new diagnostics by utilizing Lilly’s Fab Phage Display Library, advancing innovations from discovery to the clinic The collaboration will speed up the discovery and validation of new antibodies and enhances IBRI’s capabilities to develop Ab targeting range of diseases […]Read More